EFFICACY OF ATRASENTAN BY RENIN–ANGIOTENSIN SYSTEM INHIBITOR DOSE IN IgA NEPHROPATHY PATIENTS FROM EAST ASIA: POST HOC ANALYSIS FROM THE PHASE III ALIGN TRIAL

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/6eec1a65f40b52b0f89806630e356c66.pdf
EFFICACY OF ATRASENTAN BY RENIN–ANGIOTENSIN SYSTEM INHIBITOR DOSE IN IgA NEPHROPATHY PATIENTS FROM EAST ASIA: POST HOC ANALYSIS FROM THE PHASE III ALIGN TRIAL

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Hong
Zhang
Hong Zhang hongzh@bjmu.edu.cn Peking University First Hospital Renal Division Beijing China *
Jonathan Barratt jb81@leicester.ac.uk University of Leicester The Mayer IgA Nephropathy Laboratories Leicester United Kingdom - Leicester General Hospital The John Walls Renal Unit Leicester United Kingdom
Hiddo JL Heerspink h.j.lambers.heerspink@med.umcg.nl University of Groningen, University Medical Center Groningen Department of Clinical Pharmacy and Pharmacology Groningen Netherlands -
Meg J Jardine meg.jardine@sydney.edu.au University of Sydney NHMRC Clinical Trials Centre Sydney Australia -
Donald E Kohan donald.kohan@hsc.utah.edu University of Utah Heath Division of Nephrology Salt Lake City United States -
Adeera Levin ALevin@providencehealth.bc.ca The University of British Columbia Division of Nephrology Vancouver Canada -
Adrian Liew draliew2@gmail.com Mount Elizabeth Novena Hospital The Kidney and Transplant Practice Singapore Singapore -
Suparna Mallik suparna.mallik@novartis.com Novartis Pharmaceuticals Corporation Global Medical Affairs East Hanover United States -
Ankit B Patel ankit-6.patel@novartis.com Novartis Pharmaceuticals Corporation Clinical Development East Hanover United States -
Elena Morris elena.morris@novartis.com Novartis Pharmaceuticals Corporation Clinical Development East Hanover United States -
Yuhan Li yuhan-1.li@novartis.com Novartis Pharmaceuticals Corporation Global Medical Affairs East Hanover United States -
Marion Dahlke marion.dahlke@novartis.com Novartis Pharma AG Clinical Development Basel Switzerland -
Richard Lafayette czar@stanford.edu Stanford University Division of Nephrology Stanford United States -